Year: 2018
Type: review
Abstract: Iron chelation has been introduced as a new therapeutic concept for the treatment of neurodegenerative diseases with features of iron overload. At difference with iron chelators used in systemic diseases, effective chelators for the treatment of neurodegenerative diseases must cross the blood⁻brain barrier. Given the promissory but still inconclusive results obtained in clinical trials of iron chelation therapy, it is reasonable to postulate that new compounds with properties that extend beyond chelation should significantly improve these results. Desirable properties of a new generation of chelators include mitochondrial destination, the center of iron-reactive oxygen species interaction, and the ability to quench free radicals produced by the Fenton reaction. In addition, these chelators should have moderate iron binding affinity, sufficient to chelate excessive increments of the labile iron pool, estimated in the micromolar range, but not high enough to disrupt physiological iron homeostasis. Moreover, candidate chelators should have selectivity for the targeted neuronal type, to lessen unwanted secondary effects during long-term treatment. Here, on the basis of a number of clinical trials, we discuss critically the current situation of iron chelation therapy for the treatment of neurodegenerative diseases with an iron accumulation component. The list includes Parkinson's disease, Friedreich's ataxia, pantothenate kinase-associated neurodegeneration, Huntington disease and Alzheimer's disease. We also review the upsurge of new multifunctional iron chelators that in the future may replace the conventional types as therapeutic agents for the treatment of neurodegenerative diseases.
Source: Pharmaceuticals
DOI: 10.3390/ph11040109
Authors: Marco T. Nuñez, Pedro Chana-Cuevas
Institutions: University of Chile, Universidad de Santiago de Chile
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: iron chelation therapy, neurodegenerative diseases, iron overload, blood-brain barrier, mitochondrial iron, reactive oxygen species, Fenton reaction, labile iron pool, iron homeostasis, Parkinson's disease, Friedreich's ataxia, pantothenate kinase-associated neurodegeneration, Huntington's disease, Alzheimer's disease, iron chelators
Open Access status: gold
Estimated APC paid: $3,499
Award: G6249885766
OpenAlex ID: W2897222476
